ENDRA Life Sciences (NDRA) Non-Current Debt (2020 - 2023)

ENDRA Life Sciences (NDRA) has reported Non-Current Debt for 4 consecutive years, with $281154.0 the latest figure, recorded in Q2 2023.

• On a quarterly basis, Non-Current Debt fell 40.52% year-over-year to $281154.0 in Q2 2023; TTM through Jun 2023 was $281154.0, a 40.52% decrease from a year earlier, with the FY2021 full-year figure at $546631.0, down 10.24% from the prior year.
• Non-Current Debt was $281154.0 for Q2 2023 at ENDRA Life Sciences, down from $324064.0 in the prior quarter.
• Over five years, Non-Current Debt peaked at $614677.0 in Q2 2021 and troughed at $28484.0 in Q1 2021.
• A 4-year average of $423041.2 and a median of $453454.5 in 2022 frame the typical range for Non-Current Debt.
• Across the five-year window, Non-Current Debt surged 1690.84% in 2022 and plunged 40.52% in 2023, its largest moves.
• Over 4 years, Non-Current Debt stood at $608992.0 in 2020, then slipped by 10.24% to $546631.0 in 2021, then slipped by 20.56% to $434257.0 in 2022, then sank by 35.26% to $281154.0 in 2023.
• The last three Non-Current Debt figures came in at $281154.0 (Q2 2023), $324064.0 (Q1 2023), and $434257.0 (Q3 2022), per Business Quant data.